Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FB-101 in Healthy Subjects
NCT04165837Phase 1Completed
- Sponsor
- 1ST Biotherapeutics
- Start
- Oct 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing Active (FB-101) with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2019; status: completed.
02
Drugs
FB-101
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04165837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165837.